a cure for hep c, aids, the flu and dengue..., page-11

This must be one of the most understated companies on the ASX...Only 18 announcements so far in 2010.They aren't much for casual talk.Your overveiw was great tawnyport in that you set out the companies progess so far.Put the pieces of the puzzle together over the last few years,the broker coverage,the medical journal coverage and she looks totally undervalued.

The enemy of the SP has been time with long periods of announcement inactivity offering the opportunity to collect stock much lower than apparent value.

This has been a tough stock to get set on due to its tightly held register and low volume.To the credit of management they appear to be keeping dilution to a minimum.I believe they expect a successful phase II with their next raising to follow.

Nice to see Biotron back themselves.